• Journal of Oral Medicine and Pain
• /
• v.23 no.1
• /
• pp.37-44
• /
• 1998

본연구는 서울대학교 치과병원 구강진단과 악안면 동통진료실에 내원한 환자 중 임상적 검사에 의해 악관절 내장증으로 진단된 총 32명 53개의 측두하악 관절을 대상으로 악관절 조영술이나 자기공명영상을 실시하여 임상적 진단의 정확도를 알아보고 향후 이 결과를 적절히 활용하여 정확한 적응증의 설정에 도움을 주고자 시행되었다. 각 악관절을 임상적 검사, 조영술 및 자기공명영상 검사를 기준으로 정상, 정복성 관절원판 변위, 비정복성 관절원판 변위, 퇴행성 관절 질환을 동반한 정복성 관절원판 변위, 퇴행성 관절 질환을 동반한 비정복성 관절원판 변위로 구분하였다. 이상의 연구를 통하여 다음과 같은 결론을 얻었다. 1. 악관절 내장증으로 내원한 환자 32명, 총 53개 관절중, 정상인 경우가 5예, 정복성 관절원판 변위인 경우가 33예, 비정복성 관절원판 변위인 경우가 14예, 퇴행성 관절 질환을 동반한 정복성 관절원판변위인 경우가 1예이었고, 퇴행성 관절 질환을 동반한 비정복성 관절원판 변위인 경우는 없었다. 2. 악관절 조영술 검사를 시행한 35개의 관절중 임상적 검사와 일치하는 경우는 32개로 그 일치율은 91.1%이었으며, 자기공명영상 검사를 시행한 28개의 관절중 임상적 검사와 일치하는 경우는 20개로 그 일치율은 71.4%이었다. 3. 악관절 조영술 및 자기공명영상 검사를 동시에 시행한 10개 관절중 악관절 조영술 및 자기공명영상검사가 일치하는 경우는 9개이었으며 이중 8개 결과는 임상적 진단과 일치되는 소견을 보였다. 임상적 검사는 악관절 내장증의 진단에 유용한 방법임이 확인되었다. 그러나 임상적으로는 정상으로 진단되었지만 주관적인 증상을 가진 환자에게는 자기공명영상 검사와 악관절조영술 검사 등의 영상진단술식이 필요할 것으로 사료된다.

• Korean Journal of Clinical Laboratory Science
• /
• v.36 no.1
• /
• pp.64-68
• /
• 2004

Brain death is defined as the irreversible cessation of all brain function. The diagnosis of brain death is primarily based on a careful neurological examination demonstrating unresponsiveness, absent of brain stem reflexes, and no respiratory activity. Several conditions which may mimic brain death must be excluded. In some cases investigations such as electroencephalography, angiography, transcranial doppler or evoked potentials can contribute to the diagnosis. The brief review will introduce medical technologist and clinician to the key issues in the definition and management of brain death.

• Korean Journal of Clinical Laboratory Science
• /
• v.54 no.1
• /
• pp.49-60
• /
• 2022

This study attempted to provide the basic data for developing a system to identify the role of medical technologists and ensure an efficient response for quick and accurate diagnostic tests in the COVID-19 era. The research method involved using focus group interviews for a survey and analysis of 15 medical institutions. Eleven sample collection institutions, 10.4 medical technologists, 2.1 minutes of collection time, 5.4 hours of test time, 9,670 tests, 6.2 member test workforce size, and 7 screening center operating institutions were surveyed. The results of the focus group interview analysis revealed that there were no standardized guidelines covering working hours, area, and environment to protect sample collectors and testers in relation to the COVID-19 tests. Also, legal protection measures were insufficient in the event of accidental infections and there were no personnel regulations related to COVID-19. In addition, the professional training of sample collectors and molecular diagnostic testers was required for reliable COVID-19 testing. In conclusion, it is necessary to provide professional education through special test short-term training institutions to cope with emergency infectious diseases such as COVID-19. Legal systems should be put in place to protect the workforce and ensure stability.

• Journal of the korean veterinary medical association
• /
• v.24 no.1
• /
• pp.19-24
• /
• 1988

A lactating Holstein cow which did not have had responded to drug therapy during 2 months was clinically examined. Right atrial vegetative endocarditis was determined dy ultrasonographic diagnosis, and later it was confirmed at necropsy. An early systolic

• Korean Journal of Clinical Laboratory Science
• /
• v.50 no.4
• /
• pp.375-381
• /
• 2018

Cytogenetic analysis plays an important role in examinations of a variety of human disorders. Over the years, cytogenetic analysis has evolved to a great extent and become a part of routine laboratory testing; the analysis provides significant diagnostic and prognostic results for human diseases. Microarray in conjunction with molecular cytogenetics and conventional chromosome analysis has transformed the outcomes of clinical cytogenetics. The advantages of microarray technologies have become obvious to the medical and laboratory community involved in genetic diagnosis, resulting in greatly improved visualization and validation capabilities. This article reviews how the field is moving away from conventional cytogenetics towards molecular approaches for the identification of pathogenic genomic imbalances and discusses practical considerations for the routine implementation of these technologies in genetic diagnosis.

• Journal of Veterinary Clinics
• /
• v.20 no.1
• /
• pp.7-11
• /
• 2003

The selection of a test as a reference with no perfect sensitivity and specificity may lead to bias, yielding distortion of the diagnostic performance. This means it is inappropriate to use imperfect diagnostic tests as a reference method to identify infected patients in clinical environments. In this study, diagnostic performance of rapid urease test, polymerase chain reaction (PCR), and histology of gastric biopsy specimens for diagnosing Helicobacter pylori infection separately and in combination was estimated by using non-linear regression. Based on this approach, the sensitivity, specificity and likelihood ration positive and negative values for each test were as follows: urease test 99.9%, 99.9%, 99.9%, 99.6%, respectively; PCR 88.6%, 99.9%, 99.9%, 70.5%, respectively; histology 78.3%, 97%, 78.3%, 97%, respectively. Predictive values for positive and negative changes with varying Combination of three diagnostic tests employed in the study gives no substantial benefit for practitioners to screen infected patients, and urease test or PCR represents an appropriate single test in clinical environments.

• The Journal of the Korean dental association
• /
• v.37 no.3 s.358
• /
• pp.181-187
• /
• 1999

치주질환은 초기에는 환자 자신이 전혀 모르는 가운데 진행되어 환자가 증상을 느낄 때 쯤되면 이미 병변이 상당히 진행된 상태가 되어 치료하기 어려운 경우가 많게 되므로 치주질환의 원인과 질병상태를 조기에 파악하여 치료하는 것이 중요하다. 치주질환을 진단하는데 있어서는 객관적인 임상적 기준을 필요로 하게되며 치주질환의 활성도를 알아보기위해서는 여러 임상적 변수가 동시에 필요하므로 우선 환자의 병력을 파악하고 구강의 및 구강내 검사를 완전히 시행한 후 환자의 치아의 치주조직상태를 검사하게 된다. 이 장에서는치주질환의 진단에 필수적인 요인인 치아와 치주조직 검사에 대하여 중점적으로 애기 하고자 한다.

• Korean Journal of Clinical Laboratory Science
• /
• v.50 no.4
• /
• pp.382-390
• /
• 2018

The history of the pregnancy test started in ancient Egypt with a germination test using wheat and barley. Since then, unscientific methods have been used from the days of Hippocrates and Galen to the Middle Ages when uroscopy was used, even until the early 1800s. On the other hand, since the mid-1800s, scientific methods and evidence have begun to emerge, which led to scientific research on the physiological characteristics of pregnancy. The first attempt to utilize these scientific findings was initiated with the bioassay by Aschheim and Zondek using rats and mice in 1927, and then developed into experiments using rabbits and frogs. The immunoassay method, which started in the 1960s, contributed greatly to the generalization of the pregnancy tests while improving the problems of the bioassay. In 1976, a pregnancy test kit was introduced that can be used at home, contributing to the popularization of pregnancy tests. Since the 1980s, technological advances in diagnostic tests have also been applied to pregnancy tests to further improve the reliability of the diagnosis of pregnancy. In the 2000s, the accuracy and ease of use of the pregnancy test kits for home use have improved drastically. This study examined the history and scientific development of the pregnancy test.

• Review of Korea Contents Association
• /
• v.15 no.3
• /
• pp.27-33
• /
• 2017

• Journal of Genetic Medicine
• /
• v.8 no.1
• /
• pp.28-34
• /
• 2011

Most clinicians understand clinical trials as the evaluation process for new medicine before their use. However, clinical trials can also be applied to laboratory diagnostic tests (LDTs) to verify diagnostic accuracy and efficacy before their clinical laboratory implementation for patients. The clinical trial of LDT has two distinctive characteristics that are different from the case of pharmaceuticals and thus worth special consideration. One of them is the level of evidence. The well-designed randomized controlled trials (RCTs) are known to provide the best evidence to prove the clinical efficacy of any pharmaceutical products. However, RCTs lose practicality when applied to LDTs due to various issues including ethical complications. For this reason, comparative study format is considered more feasible approach for LDTs. In addition pharmaceuticals and LDTs are different in that the user's intervention is not required for the former but critical to the latter. Moreover, in the case of pharmaceuticals, end-products are produced by manufacturers before being used by clinicians. However, in LDTs, once reagents and instruments are provided by manufacturers, they are first utilized by clinical laboratories to produce test results in order for clinicians to use them later. In other words, when it comes to LDTs, clinical laboratories play the role of manufacturers, providing reliable test results with improved quality assurance. Considering the distinctive characteristics of LDTs, we would like to offer detailed suggestions to successfully perform clinical trials in LDTs, which include analytical performance measures, clinical test performance measures, diagnostic test accuracy measures, clinical effectiveness measures, and post-implementation surveillance.